Metabotropic P2Y purinoceptor-mediated presynaptic and postsynaptic enhancement of cerebellar GABAergic transmission.
Cerebellar GABAergic inhibitory transmission is under heterosynaptic control mediated by diverse chemical messengers. Here, we investigated roles of metabotropic P2Y purinoceptors (P2YRs) on GABAergic synapses between cerebellar interneurons and Purkinje cells (PCs). Activation of P2Y purinoceptors by two selective agonists, ADP and 2-methylthio-ADP (2MeSADP), elicited two distinct forms of synaptic plasticity of GABAergic transmission in the cerebellar cortex. First, the two agonists induced long-lasting enhancement of stimulation-evoked GABAergic IPSCs as well as GABA(A) receptor currents in PCs. This effect was completely abolished by intracellular infusion of the Ca2+-chelating agent BAPTA. Measurements of intracellular Ca2+ ([Ca2+]i) dynamics showed that puff application of 2MeSADP produced an increase in [Ca2+]i of PCs and that this increase persisted in an external Ca2+-deficient medium. These results suggest that P2Y activation postsynaptically elicits long-term enhancement of GABA(A) receptor sensitivity of PCs through a Gq-mediated increase in [Ca2+]i. The other action of P2YR agonists on cerebellar GABAergic synapses was that they produced a short-term increase in the frequency and the amplitude of spontaneous GABAA receptor-mediated IPSCs in PCs in a manner sensitive to a P2Y1R antagonist, N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. This action appeared to be attributable to an excitability increase in presynaptic GABAergic interneurons, because ADP excited all Lugaro cells examined and some of interneurons in the molecular layer. These results suggest that activation of cerebellar P2Y purinoceptors leads to modulation of GABAergic transmission in different spatial and temporal domains, namely short-term and long-term plasticity through presynaptic and postsynaptic mechanisms at interneuron-->PC inhibitory synapses in the rat cerebellar cortex.
Saitow
Fumihito
F
Department of Pharmacology, Nippon Medical School, Tokyo 113-8602, Japan.
Murakoshi
Takayuki
T
Suzuki
Hidenori
H
Konishi
Shiro
S
D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000502:physiology; D002525:Cerebellar Cortex / Q000166:cytology*; D002614:Chelating Agents / Q000494:pharmacology; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D007395:Interneurons / Q000187:drug effects / Q000502:physiology*; D017774:Long-Term Potentiation / Q000187:drug effects / Q000502:physiology; D008297:Male; D009457:Neuroglia / Q000502:physiology; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology*; D018408:Patch-Clamp Techniques; D011689:Purkinje Cells / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D011963:Receptors, GABA-A / Q000502:physiology; D017661:Receptors, Presynaptic / Q000187:drug effects / Q000502:physiology*; D018048:Receptors, Purinergic P2 / Q000187:drug effects / Q000502:physiology*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*; D013779:Tetrodotoxin / Q000494:pharmacology; D013873:Thionucleotides / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D002614:Chelating Agents; C111914:N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate; D011963:Receptors, GABA-A; D017661:Receptors, Presynaptic; D018048:Receptors, Purinergic P2; D013873:Thionucleotides; D014970:Xanthines; C002480:methylthio-ADP; D013779:Tetrodotoxin; D004533:Egtazic Acid; D005680:gamma-Aminobutyric Acid; D000244:Adenosine Diphosphate; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; C051360:1,3-dipropyl-8-cyclopentylxanthine; C025603:1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; D002118:Calcium
Mol Cell Neurosci. 1998 Nov;12(4-5):300-10
9828093
Nature. 2003 Nov 20;426(6964):285-91
14614461
J Neurosci. 2001 Sep 1;21(17):6522-31
11517241
J Neurosci. 2000 May 1;20(9):3067-75
10777770
J Neurosci. 2003 Aug 13;23(19):7426-37
12917379
Neuron. 2003 Dec 4;40(5):971-82
14659095
Neuron. 1991 Apr;6(4):565-74
2015092
Science. 2001 May 4;292(5518):926-9
11340205
J Physiol. 2003 Nov 1;552(Pt 3):777-87
12949218
Curr Opin Neurobiol. 2001 Jun;11(3):387-94
11399439
Neuropharmacology. 2002 Mar;42(4):476-88
11955519
J Neurosci. 2005 Feb 23;25(8):2108-16
15728851
Pharmacol Toxicol. 1995 May;76(5):302-7
7567779
Nature. 1992 Jun 11;357(6378):503-5
1351659
Pharmacol Rev. 1998 Sep;50(3):413-92
9755289
J Neurosci. 1997 Jul 1;17(13):5062-9
9185543
Brain Res. 1993 Apr 23;609(1-2):262-8
8508308
Physiol Rev. 2002 Oct;82(4):1013-67
12270951
J Neurosci. 1995 Dec;15(12):7861-71
8613725
Neuron. 2003 Dec 18;40(6):1173-83
14687551
Curr Opin Neurobiol. 1997 Jun;7(3):346-57
9232809
Neuroreport. 2000 Nov 27;11(17):3799-803
11117494
J Neurosci. 2000 Mar 1;20(5):1837-48
10684885
J Physiol. 2003 Jul 15;550(Pt 2):493-504
12807993
J Biol Chem. 2002 Oct 25;277(43):40324-34
12138101
J Comp Neurol. 2000 Jun 5;421(3):374-84
10813793
J Neurosci. 1998 Mar 1;18(5):1704-12
9464995
J Neurosci. 1999 Jan 15;19(2):520-8
9880572
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13351-6
8917594
Nature. 1992 Apr 16;356(6370):601-4
1313949
J Pharmacol Exp Ther. 2000 Apr;293(1):172-9
10734167
J Physiol. 1996 Dec 15;497 ( Pt 3):611-27
9003548
Nature. 2003 Dec 4;426(6966):517-24
14654832
J Neurosci. 2003 Jun 1;23(11):4457-69
12805286
Nat Rev Neurosci. 2001 Mar;2(3):185-93
11256079
J Neurosci. 1995 Apr;15(4):2961-71
7722640
J Neurophysiol. 2000 Oct;84(4):2016-25
11024094
J Neurosci. 1999 Jan 15;19(2):737-46
9880594
J Med Chem. 2000 Mar 9;43(5):829-42
10715151
Am J Physiol Heart Circ Physiol. 2001 Oct;281(4):H1759-66
11557568
J Neurosci. 2003 Jul 30;23(17):6728-39
12890765
J Physiol. 2002 May 1;540(Pt 3):851-60
11986374
Neuroscientist. 2001 Jun;7(3):207-19
11499400
J Neurophysiol. 2003 Jun;89(6):3243-52
12783958
Neuroscience. 1996 Aug;73(3):643-7
8809785
J Neurochem. 2001 Apr;77(1):84-93
11279264